PT  - JOURNAL ARTICLE
AU  - Yang, Lu
AU  - Bolton, Elliot
AU  - Nayar, Gowri
AU  - Altman, Russ B.
TI  - Longitudinal modeling of multimorbidity trajectories using large language models
AID  - 10.1101/2024.10.02.24314786
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.02.24314786
4099  - http://medrxiv.org/content/early/2024/10/03/2024.10.02.24314786.short
4100  - http://medrxiv.org/content/early/2024/10/03/2024.10.02.24314786.full
AB  - Multimorbidity, the co-occurrence of two or more chronic conditions within an individual, is a major and escalating global health challenge, complicating treatment regimens, straining healthcare resources, and worsening patient outcomes. The complex interplay of shared genetic predispositions, biological pathways, and socioeconomic factors underpins its development, but clinical and research efforts have largely focused on managing diseases in isolation. Understanding multimorbidity trajectories—the accumulation and interaction of chronic diseases over time—is essential to improving preventive strategies and optimizing personalized care. Here, we introduce ForeSITE (Forecasting Susceptibility to Illness with Transformer Embeddings), a novel, transformer-based framework that harnesses advanced machine learning to predict multimorbidity progression. By analyzing longitudinal data from 480,000 participants in the UK Biobank, ForeSITE identifies distinct patterns in the co-occurrence and timing of diseases. Our temporal disease network provides insights into how certain diseases might share common genetic, environmental, or socioeconomic factors, offering more specific guidance for earlier detection and more effective disease management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH GM102365 and the Chan-Zuckerberg Biohub.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of UK Biobank gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access